Bell JC - Search Results

1

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.

Wedge ME, Jennings VA, Crupi MJF, Poutou J, Jamieson T, Pelin A, Pugliese G, de Souza CT, Petryk J, Laight BJ, Boileau M, Taha Z, Alluqmani N, McKay HE, Pikor L, Khan ST, Azad T, Rezaei R, Austin B, He X, Mansfield D, Rose E, Brown EEF, Crawford N, Alkayyal A, Surendran A, Singaravelu R, Roy DG, Migneco G, McSweeney B, Cottee ML, Jacobus EJ, Keller BA, Yamaguchi TN, Boutros PC, Geoffrion M, Rayner KJ, Chatterjee A, Auer RC, Diallo JS, Gibbings D, tenOever BR, Melcher A, Bell JC, Ilkow CS. Wedge ME, et al. Among authors: bell jc. Nat Commun. 2022 Apr 7;13(1):1898. doi: 10.1038/s41467-022-29526-8. Nat Commun. 2022. PMID: 35393414 Free PMC article.

2

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. Stojdl DF, et al. Among authors: bell jc. Cancer Cell. 2003 Oct;4(4):263-75. doi: 10.1016/s1535-6108(03)00241-1. Cancer Cell. 2003. PMID: 14585354 Free article.

3

Recent progress in the battle between oncolytic viruses and tumours.

Parato KA, Senger D, Forsyth PA, Bell JC. Parato KA, et al. Among authors: bell jc. Nat Rev Cancer. 2005 Dec;5(12):965-76. doi: 10.1038/nrc1750. Nat Rev Cancer. 2005. PMID: 16294217 Review.

4

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC. Power AT, et al. Among authors: bell jc. Mol Ther. 2007 Jan;15(1):123-30. doi: 10.1038/sj.mt.6300039. Mol Ther. 2007. PMID: 17164783 Free article.

5

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

Power AT, Bell JC. Power AT, et al. Among authors: bell jc. Mol Ther. 2007 Apr;15(4):660-5. doi: 10.1038/sj.mt.6300098. Epub 2007 Jan 30. Mol Ther. 2007. PMID: 17264852 Free article. Review.

6

Oncolytic viruses: what's next?

Bell JC. Bell JC. Curr Cancer Drug Targets. 2007 Mar;7(2):127-31. doi: 10.2174/156800907780058844. Curr Cancer Drug Targets. 2007. PMID: 17346103 Review.

7

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC. Breitbach CJ, et al. Among authors: bell jc. Mol Ther. 2007 Sep;15(9):1686-93. doi: 10.1038/sj.mt.6300215. Epub 2007 Jun 19. Mol Ther. 2007. PMID: 17579581 Free article.

8

Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?

Stanford MM, Breitbach CJ, Bell JC, McFadden G. Stanford MM, et al. Among authors: bell jc. Curr Opin Mol Ther. 2008 Feb;10(1):32-7. Curr Opin Mol Ther. 2008. PMID: 18228179 Review.

9

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.

Power AT, Bell JC. Power AT, et al. Among authors: bell jc. Gene Ther. 2008 May;15(10):772-9. doi: 10.1038/gt.2008.40. Epub 2008 Mar 27. Gene Ther. 2008. PMID: 18369325 Review.

10

A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC. Edge RE, et al. Among authors: bell jc. Mol Ther. 2008 Aug;16(8):1437-43. doi: 10.1038/mt.2008.130. Epub 2008 Jun 17. Mol Ther. 2008. PMID: 18560417 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

376 results

Search Page

Filters